Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    Certain Biomarkers Have Limitations in Predicting Cardiovascular Events - (DGNews)
    TopAbstracts in Cholesterol/Lipid Disorders 06/25/2009 - (DGNews)
    Treatment With Physiological Levels of Growth Hormone Fails to Show Benefit on Cardiovascular Parameters: Presented at ENDO 09 - (DGDispatch)
    Genetically elevated lipoprotein(a) and increased risk of myocardial infarction - (JAMA)
    TopAbstracts in Cholesterol/Lipid Disorders 06/11/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
      The Evolution of Cardiometabolic Risk Reduction and Mixed Dyslipidemia: Examining the Role of Chronic Obesity Management
      Treatment of Mixed Dyslipidemia
      Artifactual Laboratory Abnormalities in Patients with Paraproteinemia
      Issues in Cardiovascular & Metabolic Risk Management: Highlights from ENDO 08
      Dyslipidemia in Children and Adolescents

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        Marked Aortic Valve Stenosis Progression After Receiving Long-Term Aggressive Cholesterol-Lowering Therapy Using Low-Density Lipoprotein Apheresis in a Patient With Familial Hypercholesterolemia
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia
        Abetalipoproteinemia: Two Case Reports and a Literature Review
        Familial Hypercholesterolemia with Coarctation of Aorta

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Atorvastatin Has No Clinical Effect on Gonadal or Adrenal Steroid Hormones

        A DGReview of :"Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia"
        Journal of Atherosclerosis and Thrombosis

        11/03/2003
        By Mary Beth Nierengarten


        Atorvastatin therapy for hypercholesterolaemia has no clinical effect on gonadal or adrenal steroid hormones in patients with type 2 diabetes, reports a study from Italy.

        Atorvastatin, a second generation synthetic 3-hydroxy 3-mthylglutaryl-coenzyme-A reductase inhibitor, is used treat hypercholesterolaemia, a condition that must be aggressively treated in patients with type 2 diabetes. However, along with reducing intracellular cholesterol synthesis and serum cholesterol levels, atorvastatin may also negatively effect gonadal and adrenal steroidogenesis.

        SA Santini, MD and colleagues, Catholic University of Medicine, Rome conducted a study to assess the effect of atorvastatin on gonadal and adrenal hormones in a cohort of patients with type 2 diabetes. Therapeutic doses of atorvastatin (20 mg/day) were given to 24 patients with type 2 diabetes (16 males, 8 postmenopausal females) with mild (LDL-cholesterol of 150.1 ± 32.0 mg/dl) or moderate (LDL-cholesterol of 189.9 ± 32.9 mg/dl) hypercholesterolaemia. Patients were evaluated before and after 3 months of atorvastatin therapy.

        Measurements taken from all patients included lipids and serum cortisol, dehydroepiandrosterone sulphate (DHEA-S), androstendione, and sex hormone binding globulin (SHBG). Testosterone and free testosterone index were also measured in males.

        A significant decrease in total and LDL cholesterol was observed after atorvastatin therapy (P < .05), with no significant changes in HDL-cholesterol. Significance was not found in any of the patients between steroid hormones measured before or after administration of atorvastatin.

        The authors conclude that atorvastatin does not clinically effect gonadal or adrenal steroid hormones in patients with type 2 diabetes.

        J Atheroscler Thromb 2003;10:3:160-4. "Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send